Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Amphotericin B for Cutaneous Leishmaniasis in the Elderly
NCT06449040Phase 2Completed
- Sponsor
- Hospital Universitário Professor Edgard Santos
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal amphotericin b in cutaneous leishmaniasis (CL) (3 arms), sponsored by Hospital Universitário Professor Edgard Santos. Primary endpoint: Total initial cicatrization. Started Mar 2019; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06449040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449040.